このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

手術部位の感染を減らすためのFALCON試験試験対策 (FALCON)

2026年11月11日 更新者:University of Birmingham

低所得国および中所得国における手術部位感染を減らすための実用的な多施設共同無作為対照試験試験対策

FALCON is a Pragmatic multi-centre trial testing measures to reduce superficial or deep skin infection following abdominal surgery in low and middle income countries. The trial will recruit patients undergoing abdominal surgery. Recruited participants will be randomly assigned to four arms to receive different combinations of skin preparation and sutures for would closure:

A. In this arm surgeon will use 2% alcoholic chlorhexidine for skin cleansing and non-coated suture for wound closure; B. In this arm surgeon will use 2% alcoholic chlorhexidine for skin cleansing and triclosan coated suture for wound closure; C. In this arm surgeon will use for operation 10% aqueous povidone-iodine for skin cleansing and non-coated suture for wound closure; D. In this arm surgeon will use 10% aqueous povidone-iodine for skin cleansing and triclosan-coated suture.

調査の概要

詳細な説明

FALCON is a pragmatic, blinded (patient and outcome assessor), 2x2 factorial, stratified, multi-centre randomised controlled trial, with an internal pilot, to evaluate measures to reduce Surgical Site Infection (SSI) rates in patients undergoing surgery with an abdominal incision.

Surgical site infection (SSI) represents a major burden for patients, doctors, and health systems across all settings. SSI is the commonest postoperative complication worldwide and the commonest healthcare-associated infection in low and middle income countries (LMICs). SSIs cause pain, discomfort, disability, and increase the time taken to return to work (3). SSIs increase healthcare costs in all health settings. Whilst there is no direct data on the costs of SSI in LMICs, within the UK National Health Service, SSIs cost approximately £3500 per patient and £700 million per year in total. The impact of increased healthcare costs on patients, communities, and providers can be major in LMICs where personal income is low and patients may be required to pay for their own treatment. SSI has also been associated with one-third of postoperative deaths and accounts for 8% of all deaths caused by a hospital acquired infection.

Strata in FALCON trial are defined according to the anticipated category of wound contamination: (1) clean-contaminated and (2) contaminated/dirty. Eligible patients will be randomised at the level of the individual in a 1:1:1:1 ratio between:

A. 2% alcoholic chlorhexidine and non-coated suture B. 2% alcoholic chlorhexidine and triclosan-coated suture C. 10% aqueous povidone-iodine and non-coated suture D. 10% aqueous povidone-iodine and triclosan-coated suture.

Participant will be recruited from hospitals in Low and Middle Income Countries (LMICs). Participants who is undergoing abdominal surgery with an anticipated clean-contaminated, contaminated or dirty surgical wound will be selected to enter the trial.

The 6 month internal pilot will assess the feasibility of recruitment, compliance with treatment allocation and patient retention and follow-up rates. The main RCT will recruit 5480 participants.

研究の種類

介入

入学 (実際)

5788

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Ludhiana、インド
        • Christian Medical College and Hospital Ludhiana
      • Tamale、ガーナ
        • Tamale Teaching Hospital, Tamale
      • Lagos、ナイジェリア
        • Lagos University Teaching Hospital
      • Cotonou、ベナン
        • University of Abomey Calavi
      • Veracruz、メキシコ
        • Hospital Espanol Veracruz
      • Kigali、ルワンダ
        • University Teaching Hospital of Kigali (Hub), Kigali
      • Johannesburg、南アフリカ
        • University of the Witwatersrand

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

1秒~100年 (子、大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Patients with at least one abdominal incision that is ≥5cm (open or laparoscopic extraction site), with an anticipated clean-contaminated, contaminated or dirty surgical wound.
  • Patients undergoing emergency (surgery on an unplanned admission) or elective (surgery on a planned admission) operations.
  • Any operative indication, including trauma surgery.
  • Patient able and willing to provide written informed consent (signature or a fingerprint).
  • Paediatric and adult patients. This criteria is made country-specific. Each country decides the lower age limit for the trial. This is dependent on country-specific regulatory approvals. Age eligibility will vary by country.

Exclusion Criteria:

  • Patients with a documented or suspected allergy to iodine, shellfish, or chlorhexidine skin preparation solution.
  • Patient unable to complete post-operative follow-up (i.e. will not be contactable after discharge).

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:階乗代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:2%chlorhexidine + non-coated suture

2%alcoholic chlorhexidine + non-coated suture. Intervention: skin preparation with 2%alcoholic chlorhexidine in combination with non-coated suture for abdominal fascial closure.

Interventions:

2% alcoholic chlorhexidine non-coated suture

アクティブコンパレータ:2%chlorhexidine + coated suture

2%alcoholic chlorhexidine + triclosan-coated suture. Intervention: skin preparation with 2%alcoholic chlorhexidine in combination with triclosan-coated suture for abdominal fascia closure.

Interventions:

2% alcoholic chlorhexidine triclosan coated suture

アクティブコンパレータ:10% povidone-iodine + non-coated suture

10% povidone-iodine and non-coated suture. Intervention: skin preparation with 10% povidone-iodine in combination with non-coated suture for abdominal fascial closure.

Interventions:

10% povidone-iodine non-coated suture non-coated suture

アクティブコンパレータ:10%povidone-iodine + coated suture

10%povidone-iodine/triclosan-coated suture. Intervention: skin preparation with 10% povidone-iodine in combination with triclosan-coated suture for abdominal fascial closure.

Interventions:

10% povidone-iodine triclosan coated suture

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Surgical site infection (SSI)
時間枠:At 30-days post-surgery

Deep incisional or superficial incisional SSI which must occur within 30 days of the index operation. The infection must involve the skin, subcutaneous, muscular or fascial layers of the incision. Patient must at least have one of the following: (1) purulent discharge from wound; (2) organisms detected from wound swab; (3) Wound opened spontaneously or by a clinician AND, at the surgical wound, the patient has at least one of: pain or tenderness; localised swelling; redness; heat; systemic fever (>38°C); (4) Diagnosis of SSI by a clinician or on imaging.

At 30-days post-surgery

二次結果の測定

結果測定
メジャーの説明
時間枠
Physiological parameter - SSI at discharge from hospital
時間枠:Within 30-days post surgery from index operation

Deep incisional or superficial incisional SSI. The infection must involve the skin, subcutaneous, muscular or fascial layers of the incision and the patient must have one of the following: (1) purulent discharge from wound; (2) organisms detected from wound swab; (3) Wound opened spontaneously or by a clinician AND, at the surgical wound, the patient has at least one of: pain or tenderness; localised swelling; redness; heat; systemic fever (>38°C); (4) Diagnosis of SSI by a clinician or on imaging.

Within 30-days post surgery from index operation
Mortality - patient mortality status
時間枠:Within 30-days post surgery from index operation

Mortality within 30-days post surgery

Within 30-days post surgery from index operation
Physiological parameter - Unplanned wound opening
時間枠:Within 30-days post surgery from index operation

Whether an unplanned wound opening has occurred at abdominal surgical site within 30-days post surgery, spontaneously opened or by clinician

Within 30-days post surgery from index operation
Re-operation for SSI
時間枠:Within 30-days post surgery from index operation

Re-operation for SSI within 30-days post surgery

Within 30-days post surgery from index operation
Length of hospital stay for index admission
時間枠:Within 30-days post surgery from index operation

Length of hospital stay for index admission will be collected and will measure time from surgery to time of discharge.

Within 30-days post surgery from index operation
Participant's Readmission
時間枠:Within 30-days post surgery from index operation

Whether patient readmitted within 30-days post surgery

Within 30-days post surgery from index operation
Questionnaire - return to normal activities
時間枠:Within 30-days post surgery from index operation

Return to normal activities (e.g. work, school, or family duties) ascertained by trial specific questionnaire

Within 30-days post surgery from index operation
Resistance of organisms
時間枠:Within 30-days post surgery from index operation

Resistance of organisms detected from wound swabs to prophylactic antibiotics administered within 1 hour of incision

Within 30-days post surgery from index operation
Questionnaire - Health resource usage
時間枠:Within 30-days post surgery. Health resource usage will only be collected for adult patients (aged 18 and above) at pre-selected centres. This will include costs of post-operative visits to various healthcare professionals.

Health resource usage within 30-days post surgery ascertained by trial specific questionnaire

Within 30-days post surgery. Health resource usage will only be collected for adult patients (aged 18 and above) at pre-selected centres. This will include costs of post-operative visits to various healthcare professionals.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2018年11月29日

一次修了 (実際)

2020年9月7日

研究の完了 (実際)

2020年10月31日

試験登録日

最初に提出

2018年8月23日

QC基準を満たした最初の提出物

2018年10月5日

最初の投稿 (実際)

2018年10月9日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月16日

QC基準を満たした最後の更新が送信されました

2026年11月11日

最終確認日

2019年9月1日

詳しくは

本研究に関する用語

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する